CMV-specific T-cell reconstitution prior to and after the transfer of polyclonal CMV-specific T-cell lines
| Patient no. . | Proliferation to CMV3-150 . | CMV-specific CD4+ T cells3-151 . | CMV peptide-specific CD8+T cells3-151 . | Outcome3-152 . | |||
|---|---|---|---|---|---|---|---|
| Prior to . | After . | Prior to . | After . | Prior to . | After . | ||
| 1 | − | − | nt | nt | nt | nt | CMV encephalitis d + 42 |
| 2 | − | + | 0.22 | 1.58 | 5.47 (A1) | 41.58 (A1) | IA d + 128 |
| 3 | − | + | 0.04 | 7.93 | 3.52 (A2) | 1.26 (A2) | Alive and well d + 610 |
| 4 | − | + | nt | nt | − | 13 (A2) | IA d + 177 |
| 5 | − | + | − | 0.4 | − | 3.52 (A2) | Alive and well d + 492 |
| 6 | − | + | 1.49 | 4.19 | 4.02 (A1) | 4.01 (A1) | Alive and well d + 735 |
| 7 | − | (+)3-153 | nt | 0.98 | nt | − (A11) | RSV-IP d + 389 |
| 8 | nt3-155 | + | 1 (d + 5)3-155 | 2.87 (d + 11) | 0 (d + 5)3-155 | 1.12 (A11)(d + 11) | Relapse (lymphoma) d + 36 |
| Patient no. . | Proliferation to CMV3-150 . | CMV-specific CD4+ T cells3-151 . | CMV peptide-specific CD8+T cells3-151 . | Outcome3-152 . | |||
|---|---|---|---|---|---|---|---|
| Prior to . | After . | Prior to . | After . | Prior to . | After . | ||
| 1 | − | − | nt | nt | nt | nt | CMV encephalitis d + 42 |
| 2 | − | + | 0.22 | 1.58 | 5.47 (A1) | 41.58 (A1) | IA d + 128 |
| 3 | − | + | 0.04 | 7.93 | 3.52 (A2) | 1.26 (A2) | Alive and well d + 610 |
| 4 | − | + | nt | nt | − | 13 (A2) | IA d + 177 |
| 5 | − | + | − | 0.4 | − | 3.52 (A2) | Alive and well d + 492 |
| 6 | − | + | 1.49 | 4.19 | 4.02 (A1) | 4.01 (A1) | Alive and well d + 735 |
| 7 | − | (+)3-153 | nt | 0.98 | nt | − (A11) | RSV-IP d + 389 |
| 8 | nt3-155 | + | 1 (d + 5)3-155 | 2.87 (d + 11) | 0 (d + 5)3-155 | 1.12 (A11)(d + 11) | Relapse (lymphoma) d + 36 |
nt indicates not tested; IA, invasive aspergillosis; RSV-IP, respiratory syncytial virus interstitial pneumonitis.
Data indicate whether CMV-specific T-cell proliferation was detectable (SI ≥ 3).
The maximal number of CMV protein- and peptide-specific T cells documented within 2 months after transfer is expressed as n/μL.
Day + n refers to days after T-cell transfer.
Borderline positive.
Data obtained 5 days after transfer; sample prior to T-cell therapy not evaluable.